Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
On February 15, the Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar Pharmaceutical (Carephar) was officially approved for sales in market. Shanghai Medicilon Inc. (Medicilon), as a partner of Carephar, with its solid research and development capabilities, has provided Carenoprazan’s research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved. Medicilon Drug Discovery Services Open the door to innovative medicine with science and expertise Drug discovery is the first stage of drug development and a key element that directly affects the success of new drug development. As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon can provide one-stop service for drug discovery after 19 years of intensiv...